247 related articles for article (PubMed ID: 37123549)
21. Tumor microenvironment manipulates chemoresistance in ovarian cancer (Review).
Zhang Q; Ding J; Wang Y; He L; Xue F
Oncol Rep; 2022 May; 47(5):. PubMed ID: 35362546
[TBL] [Abstract][Full Text] [Related]
22. DNA Methylation in Epithelial Ovarian Cancer: Current Data and Future Perspectives.
Papakonstantinou E; Androutsopoulos G; Logotheti S; Adonakis G; Maroulis I; Tzelepi V
Curr Mol Pharmacol; 2021; 14(6):1013-1027. PubMed ID: 32778046
[TBL] [Abstract][Full Text] [Related]
23. Is There a Role for Epigenetic Therapies in Modulating DNA Damage Repair Pathways to Enhance Chemotherapy and Overcome Drug Resistance?
Garner IM; Brown R
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326684
[TBL] [Abstract][Full Text] [Related]
24. DNA methyltransferase inhibitors influence on the DIRAS3 and STAT3 expression and in vitro migration of ovarian and breast cancer cells.
Nowak EM; Poczęta M; Bieg D; Bednarek I
Ginekol Pol; 2017; 88(10):543-551. PubMed ID: 29192415
[TBL] [Abstract][Full Text] [Related]
25. Coexpression network analysis identified Krüppel-like factor 6 (KLF6) association with chemosensitivity in ovarian cancer.
Chen Y; Bi F; An Y; Yang Q
J Cell Biochem; 2019 Feb; 120(2):2607-2615. PubMed ID: 30206992
[TBL] [Abstract][Full Text] [Related]
26. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
27. Age-associated epigenetic changes in mammalian sperm: implications for offspring health and development.
Ashapkin V; Suvorov A; Pilsner JR; Krawetz SA; Sergeyev O
Hum Reprod Update; 2023 Jan; 29(1):24-44. PubMed ID: 36066418
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers.
Huang RL; Gu F; Kirma NB; Ruan J; Chen CL; Wang HC; Liao YP; Chang CC; Yu MH; Pilrose JM; Thompson IM; Huang HC; Huang TH; Lai HC; Nephew KP
Epigenetics; 2013 Jun; 8(6):624-34. PubMed ID: 23774800
[TBL] [Abstract][Full Text] [Related]
29. Methylomic Signatures of High Grade Serous Ovarian Cancer.
Cardenas H; Fang F; Jiang G; Perkins SM; Zhang C; Emerson RE; Hutchins G; Keer HN; Liu Y; Matei D; Nephew K
Epigenetics; 2021 Nov; 16(11):1201-1216. PubMed ID: 33289590
[TBL] [Abstract][Full Text] [Related]
30. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer.
Widschwendter M; Zikan M; Wahl B; Lempiäinen H; Paprotka T; Evans I; Jones A; Ghazali S; Reisel D; Eichner J; Rujan T; Yang Z; Teschendorff AE; Ryan A; Cibula D; Menon U; Wittenberger T
Genome Med; 2017 Dec; 9(1):116. PubMed ID: 29268796
[TBL] [Abstract][Full Text] [Related]
31. LAMA3 DNA methylation and transcriptome changes associated with chemotherapy resistance in ovarian cancer.
Feng LY; Huang YZ; Zhang W; Li L
J Ovarian Res; 2021 May; 14(1):67. PubMed ID: 33992120
[TBL] [Abstract][Full Text] [Related]
32. DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancers.
Gull N; Jones MR; Peng PC; Coetzee SG; Silva TC; Plummer JT; Reyes ALP; Davis BD; Chen SS; Lawrenson K; Lester J; Walsh C; Rimel BJ; Li AJ; Cass I; Berg Y; Govindavari JB; Rutgers JKL; Berman BP; Karlan BY; Gayther SA
J Exp Clin Cancer Res; 2022 Jul; 41(1):232. PubMed ID: 35883104
[TBL] [Abstract][Full Text] [Related]
33. Predicting chemoresponsiveness in epithelial ovarian cancer patients using circulating small extracellular vesicle-derived plasma gelsolin.
Gerber E; Asare-Werehene M; Reunov A; Burger D; Le T; Carmona E; Mes-Masson AM; Tsang BK
J Ovarian Res; 2023 Jan; 16(1):14. PubMed ID: 36642715
[TBL] [Abstract][Full Text] [Related]
34. Big data-based identification of methylated genes associated with drug resistance and prognosis in ovarian cancer.
Yan B; Xiong C; Huang F; Zhang M; Mo Y; Bai H
Medicine (Baltimore); 2020 Jul; 99(27):e20802. PubMed ID: 32629664
[TBL] [Abstract][Full Text] [Related]
35. Translational Theragnosis of Ovarian Cancer: where do we stand?
Perrone MG; Luisi O; De Grassi A; Ferorelli S; Cormio G; Scilimati A
Curr Med Chem; 2020; 27(34):5675-5715. PubMed ID: 31419925
[TBL] [Abstract][Full Text] [Related]
36. MiR-34c/SOX9 axis regulates the chemoresistance of ovarian cancer cell to cisplatin-based chemotherapy.
Xiao S; Li Y; Pan Q; Ye M; He S; Tian Q; Xue M
J Cell Biochem; 2019 Mar; 120(3):2940-2953. PubMed ID: 30537410
[TBL] [Abstract][Full Text] [Related]
37. Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection.
Caiado F; Maia-Silva D; Jardim C; Schmolka N; Carvalho T; Reforço C; Faria R; Kolundzija B; Simões AE; Baubec T; Vakoc CR; da Silva MG; Manz MG; Schumacher TN; Norell H; Silva-Santos B
Nat Commun; 2019 Nov; 10(1):4986. PubMed ID: 31676777
[TBL] [Abstract][Full Text] [Related]
38. GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells.
Chiam K; Centenera MM; Butler LM; Tilley WD; Bianco-Miotto T
PLoS One; 2011; 6(9):e25634. PubMed ID: 21980513
[TBL] [Abstract][Full Text] [Related]
39. The role of ABC transporters in ovarian cancer progression and chemoresistance.
Ween MP; Armstrong MA; Oehler MK; Ricciardelli C
Crit Rev Oncol Hematol; 2015 Nov; 96(2):220-56. PubMed ID: 26100653
[TBL] [Abstract][Full Text] [Related]
40. DNA hypermethylation as a chemotherapy target.
Ren J; Singh BN; Huang Q; Li Z; Gao Y; Mishra P; Hwa YL; Li J; Dowdy SC; Jiang SW
Cell Signal; 2011 Jul; 23(7):1082-93. PubMed ID: 21345368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
